首页|期刊导航|中国实验方剂学杂志|左归丸调节肠道菌群改善肾病综合征大鼠的机制

左归丸调节肠道菌群改善肾病综合征大鼠的机制OA

Mechanism of Zuogui Wan in Improving Nephrotic Syndrome in Rats Based on Regulating Gut Microbiota

中文摘要英文摘要

目的:研究左归丸通过调节肠道菌群对肾病综合征(NS)的保护作用.方法:30只雄性 SD大鼠分为 5组,每组6只,分为正常组,模型组,左归丸低、中、高剂量组,采用6.5 mg·kg-1阿霉素尾静脉注射诱导的NS大鼠模型,造模成功后,正常组和模型组给予每天 2次生理盐水(10 mL·kg-1)灌胃,左归丸低、中、高剂量组(50、100、200 mg·kg-1)给予每天 2次左归丸(10 mL·kg-1)灌胃,各组大鼠按固定时间间隔每日给药,连续8周.观察左归丸对大鼠NS的治疗作用并筛选最佳剂量,观察大鼠肾脏和肠道病理变化,采集粪便标本,采用16S rDNA测序技术检测各组大鼠肠道菌群多样性与丰度.结果:与正常组比较,模型组大鼠24 h尿蛋白、血清肌酐、尿素氮、胆固醇显著升高(P<0.01),血清白蛋白水平显著降低(P<0.01),这种变化在各给药组大鼠中得到明显改善(P<0.05,P<0.01).肾脏病理显示,正常组大鼠肾小球、肾小管完整,排列整齐;模型组大鼠肾小球萎缩,系膜区增宽,足细胞肿胀,肾小管排列紊乱,有大量管型,糖原沉积和组织纤维化明显;各给药组大鼠可见不同程度肾小球萎缩和肾小管排列紊乱.特异性蛋白测定发现模型组大鼠血清中肾损伤分子-1(KIM-1)和α1-微球蛋白升高(P<0.01),肾组织E-钙黏蛋白(E-cadherin)、足突蛋白质(Podocin)、肾病蛋白(Nephrin)显著降低(P<0.01),转化生长因子-β(TGF-β)显著升高(P<0.01);各给药组血清KIM-1和α1-微球蛋白显著降低,E-cadherin显著升高(P<0.01),TGF-β显著降低(P<0.01),左归丸高剂量组中Podocin、Nephrin升高(P<0.05).此外,模型组大鼠肠黏膜萎缩,上皮细胞水肿,杯状细胞减少,黏膜多炎性浸润;左归丸组大鼠肠屏障较完整,杯状细胞轻微减少,伴轻度炎性细胞浸润.肠道菌群测序结果显示,左归丸可以显著改善大鼠肠道菌群失衡,恢复有益菌丰度,对肠道菌群组成有显著影响.结论:左归丸可通过改善肠道菌群,保护肠屏障,从而减轻肾病综合征大鼠的肾损伤.

Objective:To investigate the protective effects of Zuogui Wan(ZGW)decoction on nephrotic syndrome(NS)through the regulation of gut microbiota.Methods:Thirty male Sprague-Dawley(SD)rats were randomly divided into five groups,with 6 rats in each group:The control group,model group,low-dose group,medium-dose group,and high-dose group.The NS rat model was induced by tail vein injection of 6.5 mg·kg-1 doxorubicin.After successful modeling,the control and model groups were gavaged with normal saline(10 mL·kg-1)twice daily,while the low-(50 mg·kg-1),medium-(100 mg·kg-1),and high-dose(200 mg·kg-1)groups were gavaged with ZGW(10 mL·kg-1)twice daily.All rats were administered at fixed intervals daily for 8 consecutive weeks.The therapeutic effects of ZGW on NS in rats were observed,and the optimal dose was screened.Renal and intestinal pathological changes in rats were examined.Fecal samples were collected,and 16S rDNA sequencing technology was used to detect the diversity and abundance of gut microbiota in each group.Results:Compared with the control group,24-hour urinary protein,serum creatinine,urea nitrogen,and cholesterol levels significantly increased in the model group(P<0.01),while serum albumin levels decreased(P<0.01).These changes were ameliorated in the treatment groups(P<0.05,P<0.01).Renal pathology revealed intact and orderly arranged glomeruli and renal tubules in the control group.In the model group,glomerular atrophy,widened mesangial areas,podocyte swelling,disordered renal tubular arrangement,and numerous casts were observed.Varying degrees of glomerular atrophy and disordered renal tubular arrangement were seen in the treatment groups.Specific protein assays revealed increased serum levels of kidney injury molecule-1(KIM-1)and α1-microglobulin(P<0.01),and significantly decreased levels of E-cadherin,Podocin,and Nephrin in renal tissues(P<0.01),along with a significant increase in transforming growth factor-β(TGF-β)(P<0.01)in the model group.In the treatment groups,serum KIM-1 and α1-microglobulin levels decreased,E-cadherin levels significantly increased(P<0.01),and TGF-β levels significantly decreased(P<0.01).Podocin and Nephrin levels increased in the high-dose group(P<0.05).Additionally,intestinal mucosal atrophy,epithelial cell edema,decreased goblet cells,and multiple inflammatory infiltrations were observed in the model group.The sequencing results of gut microbiota demonstrate that ZGW can significantly ameliorate intestinal dysbiosis in rats,restore the abundance of beneficial bacteria,and exert a profound influence on the compositional profile of gut microbiota.Conclusion:ZGW can alleviate renal injury in rats with nephrotic syndrome by improving gut microbiota and protecting the intestinal barrier.

胡鑫宇;张涂贝;胡一昕;王瑞;熊致立;蔡燕;张雪荣;王林群

湖北中医药大学,武汉 430065||湖北省中医院,武汉 430065||湖北时珍实验室,武汉 430065湖北中医药大学,武汉 430065||湖北省中医院,武汉 430065||湖北时珍实验室,武汉 430065湖北中医药大学,武汉 430065||湖北省中医院,武汉 430065||湖北时珍实验室,武汉 430065湖北省中医院,武汉 430065||湖北时珍实验室,武汉 430065湖北中医药大学,武汉 430065||湖北时珍实验室,武汉 430065湖北省中医院,武汉 430065||湖北时珍实验室,武汉 430065||中医肝肾研究及应用湖北省重点实验室,武汉 430065湖北中医药大学,武汉 430065||湖北省中医院,武汉 430065||湖北时珍实验室,武汉 430065||中医肝肾研究及应用湖北省重点实验室,武汉 430065湖北中医药大学,武汉 430065||湖北省中医院,武汉 430065||湖北时珍实验室,武汉 430065||中医肝肾研究及应用湖北省重点实验室,武汉 430065

医药卫生

左归丸肾病综合征肠道菌群大鼠

Zuogui Wannephrotic syndromegut microbiotarats

《中国实验方剂学杂志》 2026 (19)

32-41,10

第六批全国中医临床优秀人才研修项目(国中医药人教函[2025]256 号)湖北省自然科学基金(联合基金)项目(2023AFD149)湖北省中医药管理局2023-2024年度中医药青年人才项目(ZY2023Q003)

10.13422/j.cnki.syfjx.20250919

评论